Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Giles

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|February 16, 2000
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemiaS Faderl, H M Kantarjian, D A Thomas, et al.
Cancer|April 8, 1999
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remissionJ E Cortes, H M Kantarjian, S O'Brien, et al.
Nucleic Acids Research|November 29, 2008
Aspergillus genomes and the Aspergillus cloudJane E Mabey Gilsenan, Graham Atherton, Jennifer Bartholomew, et al.
Cytometry. Part B, Clinical Cytometry|August 15, 2006
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysisM R Sheikholeslami, I Jilani, M Keating, et al.
Blood|November 26, 1999
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemiaA Aguayo, E Estey, H Kantarjian, et al.
Cancer|July 10, 2001
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemiaJ Cortes, E Estey, S O'Brien, et al.
Lancet (London, England)|July 5, 2005
A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attackP M Rothwell, M F Giles, E Flossmann, et al.
International Journal of Laboratory Hematology|March 4, 2009
Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biologyW Ma, H Kantarjian, X Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Significance of FHIT expression in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, S O'Brien, et al.
Lancet (London, England)|January 30, 2007
Validation and refinement of scores to predict very early stroke risk after transient ischaemic attackS Claiborne Johnston, Peter M Rothwell, Mai N Nguyen-Huynh, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|February 16, 2000
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemiaS Faderl, H M Kantarjian, D A Thomas, et al.
Cancer|April 8, 1999
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remissionJ E Cortes, H M Kantarjian, S O'Brien, et al.
Nucleic Acids Research|November 29, 2008
Aspergillus genomes and the Aspergillus cloudJane E Mabey Gilsenan, Graham Atherton, Jennifer Bartholomew, et al.
Cytometry. Part B, Clinical Cytometry|August 15, 2006
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysisM R Sheikholeslami, I Jilani, M Keating, et al.
Blood|November 26, 1999
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemiaA Aguayo, E Estey, H Kantarjian, et al.
Cancer|July 10, 2001
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemiaJ Cortes, E Estey, S O'Brien, et al.
Lancet (London, England)|July 5, 2005
A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attackP M Rothwell, M F Giles, E Flossmann, et al.
International Journal of Laboratory Hematology|March 4, 2009
Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biologyW Ma, H Kantarjian, X Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2000
Significance of FHIT expression in chronic myelogenous leukemiaH M Kantarjian, M Talpaz, S O'Brien, et al.
Lancet (London, England)|January 30, 2007
Validation and refinement of scores to predict very early stroke risk after transient ischaemic attackS Claiborne Johnston, Peter M Rothwell, Mai N Nguyen-Huynh, et al.
Pageof 8